At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007
In Brief
A Phase 3 clinical trial evaluating Tritanrix™- HepB, Hiberix™, and 1 other intervention for Infections, Meningococcal. Completed, enrolled 168 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess the safety and reactogenicity of a booster dose of diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) at 15-18 m and to assess the immunogenicity, safety, and reactogenicity of a dose of Mencevax™ Group A, C and W135 polysaccharide meningococcal vaccine (ACW) at 24 to 30 m in primed subjects. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Study Details
Timeline
Interventions
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months